Mercado mundial de bronquitis aguda: tendencias de la industria y pronóstico hasta 2029

Análisis y tamaño del mercado de la bronquitis aguda

Se espera que el mercado mundial de la bronquitis aguda experimente un crecimiento significativo durante el período de pronóstico. El aumento de las reacciones alérgicas en todo el mundo y los mercados emergentes son los factores responsables del crecimiento de este mercado. El aumento de los casos de resfriado común y gripe que provocan problemas de tos impulsa el mercado de la bronquitis aguda. La mayoría de los casos de bronquitis aguda son causados ​​por virus y el síntoma más común de la bronquitis aguda es la tos.

Data Bridge Market Research analiza la tasa de crecimiento del mercado mundial de bronquitis aguda en el período de pronóstico 2022-2029. La CAGR esperada del mercado mundial de bronquitis aguda tiende a rondar el 4,0% en el período de pronóstico mencionado. El mercado se valoró en 4.000 millones de dólares en 2021 y crecería hasta 5.470 millones de dólares en 2029. Además de los conocimientos del mercado, como el valor de mercado, la tasa de crecimiento, los segmentos del mercado, la cobertura geográfica, los actores del mercado y el escenario del mercado, el informe de mercado seleccionado por el equipo de Data Bridge Market Research también incluye un análisis profundo de expertos, epidemiología de los pacientes, análisis de la cartera de productos, análisis de precios y marco regulatorio.

Definición de mercado

La bronquitis aguda es la inflamación de los bronquios que se conectan con la tráquea y llevan el aire a los pulmones. Esta inflamación puede ser causada por una infección viral o bacteriana. Los síntomas iniciales son un resfriado común o gripe que se propaga desde la nariz y la garganta hacia las vías respiratorias. La infección puede durar dos semanas y los casos leves pueden tratarse en casa.

Alcance y segmentación del mercado de la bronquitis aguda

Global Acute Bronchitis Market Dynamics

Drivers

• Increasing Prevalence of COPD

Rising prevalence of COPD is a major factor boosting the market growth. As per WHO 2021, COPD is the third leading cause of death worldwide, causing 3.23 million deaths in 2019. Thus, it is increasing the demand for acute bronchitis treatment.

• Growing Demand for bronchodilators

The bronchodilator segment is expected to boost the market growth. Bronchodilators are the first-line medication for bronchitis treatment as it helps in clearing airway obstruction, which is an essential parameter in acute bronchitis to ease the breathing process in patients.

Opportunities

• Rising Prevalence of Smoking

Smoking is the leading cause of preventable disease in the U.S., witnessing more than 480,000 deaths yearly, or about 1 in 5 deaths. Currently, cigarette smoking is highest among people aged 25–44 and 45–64. Thus, it creates opportunities for market growth.

• Advanced Clinical Research and Innovative Strategies

Several market players are engaged in the implementation of strategic initiatives, thereby contributing to market growth. For instance, Beta2-agonists was developed because clinicians suspect many patients also have reversible airflow restriction (as seen in asthma or chronic obstructive pulmonary disease (COPD)) contributing to the symptoms.

Restraints/Challenges

• Lack of Awareness

Lack of patient awareness about the disease and differentiated symptoms could curb the growth of the global acute bronchitis market over a forecast period.

• High Cost

The huge expenditure required for treating acute bronchitis surely hamper the market growth.

This global acute bronchitis market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global acute bronchitis market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Acute Bronchitis Market

Considering the present scenario, COVID-19 has left a major global public health crisis impacting every business. Its long-term repercussions are expected to influence industry growth during the forecast period.

The initial phase of the COVID-19 pandemic has led to a reduction in the number of patient visits that reduced the number of patients opting for bronchitis treatment, thereby impacting the market growth. The pandemic has led to an overall reduction in ambulatory adults seeking care for bronchitis in the health system and has resulted in a dramatic reduction in antibiotic prescriptions for this disease.  

Global Acute Bronchitis Market Scope

The global acute bronchitis market is segmented on the basis of type, treatment, route of administration, end-user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Viral Infection
• Bacterial Infection
• Irritants
• Others

Treatment

• Homecare
• Medication
• Others

Route of Administration

• Oral
• Parenteral Inhalational
• Others

End-Users

• Hospitals
• Specialty Clinics
• Others

Distribution Channel

• Hospitals
• Specialty Clinics
• Others

Acute Bronchitis Market Regional Analysis/Insights

The global acute bronchitis market is analysed and market size insights and trends are provided by type, treatment, route of administration, end-user and distribution channel as referenced above.

The major countries covered in the global acute bronchitis market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is the dominating region due to rising infection in children & elderly population, and rising initiatives taken by the pharmaceutical organizations.

Asia-Pacific is likely to hold the largest market share for the acute bronchitis market due to more initiatives taken by the government organizations to spread awareness and immense presence of generic manufacturers. 

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Acute Bronchitis Market Share Analysis

El panorama competitivo del mercado global de bronquitis aguda proporciona detalles por competidor. Los detalles incluidos son una descripción general de la empresa, las finanzas de la empresa, los ingresos generados, el potencial de mercado, la inversión en investigación y desarrollo, las nuevas iniciativas de mercado, la presencia global, los sitios e instalaciones de producción, las capacidades de producción, las fortalezas y debilidades de la empresa, el lanzamiento de productos, la amplitud y la variedad de productos, el dominio de las aplicaciones. Los puntos de datos anteriores proporcionados solo están relacionados con el enfoque de las empresas en relación con el mercado global de bronquitis aguda

Los actores clave que operan en el mercado global de bronquitis aguda incluyen:

• Bayer AG (Alemania)
• Industrias farmacéuticas Teva Ltd. (Israel)
• Industrias farmacéuticas Sun Ltd. (India)
• Hikma Pharmaceutical PLC (Estados Unidos)
• Amneal Pharmaceuticals LLC. (Reino Unido)
• Aurobindo Pharma (India)
• Johnsons & Johnsons Services, Inc. (Estados Unidos)
• GlaxoSmithKline Plc (Estados Unidos)

SKU-53518